Pinpoint Therapeutics believes that the company’s approach to treat therapy-resistant cancers also may be effective against COVID-19.

As the world waits with bated breath for a treatment for COVID-19, all eyes are on Gilead Science’s antiviral drug remdesivir as a potential candidate.

Researchers at the Karolinska Institute in Sweden evaluated more than 33,000 compounds on SAMHD1 to determine which ones could inhibit the effects of the enzyme on cytarabine, one of the most-used drugs for acute myeloid leukemia (AML).

Researchers tested a new drug combo that shows promise for the treatment of the childhood brain cancers diffuse midline gliomas.

A research team may have discovered a means to prevent breast cancer from spreading to other parts of the body through the blocking of a single enzyme.

GlaxoSmithKline Plc started a late-stage study testing the company’s experimental antibiotic gepotidacin in patients with urinary tract infections and gonorrhoea.

Clovis Oncology Inc. entered into a global licensing and collaboration agreement with 3B Pharmaceuticals GmbH, a private German biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for oncology indications with a high unmet medical need.

Eli Lilly and Co.’s LOXO-292, an experimental cancer drug the company acquired in January 2019 as part of an $8 billion takeover of Loxo Oncology, shrank tumors in nearly 70 percent of advanced lung cancer patients whose tumors carried specific abnormalities in the RET gene.

Endo International plc submitted a Biologics License Application to the U.S. Food and Drug Administration for collagenase clostridium histolyticum (CCH) for the treatment of cellulite in the buttocks.

Novartis, Amgen and the Banner Alzheimer’s Institute announced they are halting two pivotal Phase II/III clinical trials in the Alzheimer’s Prevention Initiative Generation Program.